Coya Therapeutics (COYA) announces that the FDA has accepted its Investigational New Drug, or IND, application for COYA 302. This proprietary immunomodulatory biologic combination therapy is being developed for the treatment of patients with amyotrophic lateral sclerosis, or ALS. The approval of the IND by the FDA triggers a $4.2M milestone payment to Coya from DRL.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Positive Outlook for Coya Therapeutics Amid Promising Developments and Financial Stability
- Coya Therapeutics Reports Increased Losses Amid Development Focus
- Coya Therapeutics files $75M mixed securities shelf
- Coya Therapeutics Highlights Q2 2025 Financial Results
- Coya Therapeutics reports Q2 EPS (36c), consensus (43c)